上市当日，亚辉龙开盘报65.00元，盘中最高报73.80元，为上市以来最高点，收报64.00元。 中国经济网北京2月3日讯亚辉龙(688575.SH)近日发布的2025年度业绩预告显示，预计2025年度实现归 属于母公司所有者的净利润为2,000.00万元至3,000.00万元，与上年同期相比，将减少27,153.36万元至 28,153.36万元，同比减少90.05%至93.37%；预计2025年度实现归属于母公司所有者的扣除非经常性损 益的净利润6,500.00万元至8,500.00万元，与上年同期相比，将减少20,233.33万元至22,233.33万元，同比 减少70.42%至77.38%。 2022年至2024年，亚辉龙的营业收入分别为39.81亿元、20.53亿元和20.12亿元；归属于上市公司股东的 净利润分别为10.12亿元、3.55亿元和3.02亿元；归属于上市公司股东的扣非净利润分别为9.55亿元、 2.20亿元和2.87亿元；经营活动产生的现金流量净额分别为15.83亿元、-7318.76万元和5.30亿元。 亚辉龙募集资金总额为60,680.00万元，募集资金净额为54,133.44万 ...

公告指出，业绩变化的主要原因是受行业政策影响，短期国内市场需求减少，导致公司营业收入及毛利 率下降。此外，公司持有的交易性金融资产因公允价值变动产生亏损，并对各项资产进行了减值准备的 计提。尽管面临挑战，公司在海外市场的营销业务稳定增长，产品研发方面也取得了一系列进展。 近日，亚辉龙发布公告称，预计2025年度归母净利润为2000万元至3000万元，同比减少90.05%至 93.37%。同时，归母净利润扣除非经常性损益后预计为6500万元至8500万元，同比减少70.42%至 77.38%。 （亚辉龙公告） (编辑：杨燕 林辰)关键字： 医疗 ...

Core Viewpoint - The company, Yahui Long Biotechnology Co., Ltd., anticipates a significant decline in net profit for the fiscal year 2025, primarily due to reduced domestic market demand and adverse industry policies [2][5]. Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 20 million and 30 million yuan for 2025, representing a decrease of 27.15 million to 28.15 million yuan, or a year-on-year decline of 90.05% to 93.37% [2]. - The forecasted net profit, excluding non-recurring gains and losses, is projected to be between 65 million and 85 million yuan, reflecting a decrease of 20.23 million to 22.23 million yuan, or a year-on-year decline of 70.42% to 77.38% [2]. Previous Year Performance - In 2024, the net profit attributable to shareholders of the parent company was 301.53 million yuan, and the net profit after excluding non-recurring gains and losses was 287.33 million yuan [4]. Reasons for Performance Change - The decline in performance is attributed to reduced market demand due to industry policy impacts, leading to lower operating revenue and gross margin compared to the previous year [5]. - The company incurred losses from fair value changes in its trading financial assets, specifically stocks of Yunkang Group [5]. - The company plans to recognize impairment losses on various assets based on prudence principles as per accounting standards [5]. - Despite challenges in domestic marketing due to medical industry policies, the company continues to focus on innovation and expanding its product offerings in key clinical areas [5]. Product Development and Achievements - By the end of 2025, the company has expanded its domestic chemiluminescence product menu to 180 items, providing comprehensive solutions for clinical testing [6]. - The company has received a national patent for a specific testing kit and has achieved significant milestones in the development of innovative biomarkers [6]. - The company actively participates in the drafting of national standards for medical automation systems, contributing to the standardization and development of laboratory automation in China [6].

Group 1 - The company, Aihuilong, announced an expected net profit attributable to shareholders of the parent company for the year 2025 to be between 20 million and 30 million yuan, representing a year-on-year decrease of 90.05% to 93.37% [1]

Group 1: Earnings Forecasts - Han's Laser expects a net profit of 1.85 billion to 2.15 billion yuan for 2025, marking a turnaround from losses in the previous year [9] - Zhongji Xuchuang anticipates a net profit increase of 89.50% to 128.17% for 2025, projecting profits between 9.8 billion to 11.8 billion yuan [2] - Perfect World forecasts a net profit of 720 million to 760 million yuan for 2025, also reversing previous losses [25] - Yihua Lifestyle expects a net profit of 8 billion to 10 billion yuan for 2025, compared to a loss of 1.696 billion yuan in the previous year [21] - Guizhou Mingzhu anticipates a staggering net profit increase of 2908.49% to 3577.04% for 2025, projecting profits between 166 million to 203 million yuan [25] - Kexing Pharmaceutical expects a net profit increase of 328.83% to 455.89% for 2025, projecting profits between 135 million to 175 million yuan [28] Group 2: Capital Raising and Investments - Newray plans to raise no more than 1.316 billion yuan through a private placement for high-performance CNC blade industrial park projects [3] - Liyang Chip intends to raise up to 970 million yuan for integrated circuit testing projects and other initiatives [4] - Kid King plans to invest 3.3 million yuan to establish a joint venture focused on online business model innovation for family consumption [6] Group 3: Industry Developments - Tianqi Lithium's subsidiary has produced its first batch of chemical-grade lithium concentrate as part of its expansion project [5] - Yihua Lithium's subsidiary has signed a framework agreement with Indonesian state-owned enterprises to collaborate on the entire supply chain for electric vehicle batteries [7] - Longyuan Power expects a net profit increase of 51% to 73% for 2025, driven by improved profitability in its core thermal power business and expansion in renewable energy [18]

Group 1 - The company, YHLO (688575.SH), currently does not have any products related to Nipah virus testing [1] - YHLO specializes in respiratory infection immunity, particularly in Mycoplasma pneumoniae and EB virus, which are traditional projects for the company [1] - YHLO is the first domestic biotechnology company to apply chemiluminescence technology to serological testing for Mycoplasma pneumoniae and is one of the few domestic IVD suppliers capable of providing simultaneous IgG and IgM subtype testing for Mycoplasma pneumoniae and Chlamydia [1]

Core Viewpoint - The company, 亚辉龙 (688575.SH), expects a significant decline in net profit for the fiscal year 2025, projecting a decrease of 90.05% to 93.37% compared to the previous year [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is estimated to be between 20 million to 30 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between 65 million to 85 million yuan, reflecting a year-on-year decrease of 70.42% to 77.38% [1] Market Conditions - The company anticipates a reduction in domestic market demand in the short term due to industry policy impacts, which is expected to lead to a decline in both revenue and gross margin compared to the previous year [1] Asset Management - The company has reported a loss due to fair value changes in its trading financial assets, specifically related to its holdings in 云康集团有限公司 (02325.HK) [1] - In accordance with the "Enterprise Accounting Standards" and related regulations, the company plans to recognize and test impairment indicators for its assets as of December 31, 2025, and intends to make provisions for asset impairments [1]

2025年度，受行业政策影响，短期国内市场需求减少,公司本期营业收入以及毛利率较上年同期下降， 导致本期实现的营业毛利额较上年同期有所下降。此外，公司持有的交易性金融资产（云康集团有限公 司(02325.HK)的股票）因公允价值变动产生亏损。另外，根据《企业会计准则》等相关规定，基于谨慎 性原则，公司对截至2025年12月31日的各项资产进行了减值迹象的识别和测试，拟计提相关资产的减值 准备。 格隆汇1月30日丨亚辉龙(688575.SH)公布，预计2025年度实现归属于母公司所有者的净利润为2,000.00 万元至3,000.00万元，同比减少90.05%至93.37%。预计2025年度实现归属于母公司所有者的扣除非经常 性损益的净利润6,500.00万元至8,500.00万元，同比减少70.42%至77.38%。 ...

每经AI快讯，亚辉龙(688575)1月30日发布业绩预告，预计2025年度归母净利润为2000万元至3000万 元，同比减少90.05%至93.37%。2025年度，受行业政策影响，短期国内市场需求减少,公司本期营业收 入以及毛利率较上年同期下降，导致本期实现的营业毛利额较上年同期有所下降。 ...

Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between 20 million and 30 million yuan, a decrease of 27.15 million to 28.15 million yuan compared to the previous year, representing a year-on-year decline of 90.05% to 93.37%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 65 million and 85 million yuan, down by 20.23 million to 22.23 million yuan from the previous year, reflecting a year-on-year decrease of 70.42% to 77.38%[2] - The company's net profit for 2024 was 301.53 million yuan, and the net profit after deducting non-recurring gains and losses was 287.33 million yuan[3] - The decline in performance is attributed to reduced domestic market demand due to industry policies, leading to decreased operating revenue and gross margin[4] - The company has communicated with its auditing firm regarding the earnings forecast, with no significant discrepancies reported[7] Product Development and Certification - The company has expanded its domestic chemiluminescence product menu to 180 items by the end of 2025, including a complete solution for thrombus detection[5] - The company has achieved full coverage of IVDR CE Class D certification for its preoperative series of eight chemiluminescence test reagents[5] - The company has successfully obtained a national patent for an anti-Nephrin antibody detection kit and its methods[5] Industry Recognition and Standards - The company has been recognized as a national manufacturing single champion in the field of autoimmune disease diagnostics[6] - The company is actively involved in drafting national standards for automated sample processing systems, promoting standardization in laboratory automation[6]